At what enterprise value was LIBERTY DENTAL GROUP acquired in 2023?

You can find the full valuation details of LIBERTY DENTAL GROUP on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of LIBERTY DENTAL GROUP when it was acquired by OAKLEY CAPITAL INVESTMENTS?

The exact EV/EBITDA multiple for LIBERTY DENTAL GROUP is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the LIBERTY DENTAL GROUP acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the LIBERTY DENTAL GROUP deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.oakleycapital.com/news-and-insights/oakley-capital-invests-in-flemming-dental-excent-and-artinorway-group

← DATABASE

Home Database Healthcare & PharmaLIBERTY DENTAL GROUP

08/2023

LIBERTY DENTAL GROUP acquired by OAKLEY CAPITAL INVESTMENTS

GERMANY Life Sciences / Medical Devices / Implants & Prosthetics REV 1m EUR - 100m EUR

Context

Oakley Capital, through its Fund V, has successfully finalized the acquisition of Flemming Dental, Excent, and Artinorway Group in a strategic carve-out from European Dental Group (EDG). This transaction consolidates three major regional players to form one of the premier independent dental laboratory groups in Europe. The strategic rationale for the move centers on the high degree of fragmentation in the European dental lab market, which presents significant opportunities for value creation through a disciplined buy-and-build strategy. By separating these entities from a broader services provider, the group aims to establish an independent technical leader focused exclusively on the accelerating digitalization of the prosthetic and orthodontic sectors. The partnership focuses on leveraging the acquirer’s expertise in technological innovation and international expansion to scale the group’s existing network across European borders. This integration is designed to accelerate the adoption of cutting-edge CAD/CAM and 3D printing technologies, enhancing precision and delivery speed for its combined base of clinics. This transaction reinforces the group’s standing as a primary enabler of the digital transformation within the oral care supply chain, providing the strategic depth required to achieve global market leadership.

LIBERTY DENTAL GROUP, which reported an EBITDA margin of LOGIN in 2023, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Liberty Dental Group is a newly unified pan-European technology organization operating as a leading group of dental laboratories. The entity’s business model is centered on a high-tech manufacturing framework, specializing in the design and production of dental prostheses—such as crowns, bridges, and dentures—and orthodontic solutions, including braces and aligners. Its value proposition lies in the seamless integration of localized craftsmanship with advanced digital workflows, utilizing proprietary CAD software, computer-aided milling, and 3D printing. Strategically, the firm focuses on the rapid digitalization of the dental supply chain, providing high-precision components to thousands of clinics across Europe. By operating as an independent technical partner for oral care providers, the organization ensures a mission-critical role in restorative and aesthetic dentistry. The entity facilitates clinical efficiency through industrialized production and technical durability in its prosthetic materials.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2023

2022

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
10/2023	RESONETICS	NITINOL BUSINESS	UNITED STATES	Life Sciences	The takeover of the SAES Getters Nitinol business by Resonetics establishes a rare, end-to-end metallurgical capability within the medical CDMO landscape. By absorbing the complete production chain—from the furnace to the finished catheter component—the organization bypasses the traditional constraints of specialized material procurement
10/2023	LUXEMPART	ALPHACAPS	GERMANY	Life Sciences	Luxempart acquired a substantial minority stake in Alphacaps GmbH. The deal is meticulously designed to establish a long-term, highly aligned partnership between the historical owners and the incoming financial sponsor
08/2023	ATHOS CONSORTIUM	SCHÜLKE	GERMANY	Life Sciences	EQT Private Equity has agreed to sell 100% of Schülke to a consortium led by ATHOS, following a highly successful three-year transformation period. EQT originally acquired the company in a 2020 carve-out from Air Liquide for approximately €1
08/2023	CARL ZEISS MEDITEC	D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)	NETHERLANDS	Life Sciences	Eurazeo has completed the sale of D.O.R.C. to Carl Zeiss Meditec AG. This transaction marks the successful conclusion of a four-year transformation under Eurazeo's ownership, during which D.O.R.C. evolved from a European champion into a global platform
07/2023	ELOS MEDTECH	KLINGEL MEDICAL GROUP	GERMANY	Life Sciences	Elos Medtech entered into an agreement to acquire 100% of Klingel Medical Group from IK Partners and its management team. The strategic rationale for the deal is to create a market-leading European MedTech CDMO with significantly enhanced R&D capabilities and a broader technological offering
07/2023	LAUXERA	ORGANOX	UNITED KINGDOM	Life Sciences	Lauxera Capital Partners has successfully led a £25 million growth investment into OrganOx, marking a pivotal minority platform entry into the high-barrier medical technology sector. Based in Oxford, England, the commercial-stage enterprise represents a strategic addition to the investor's specialized healthcare portfolio
07/2023	EQT PARTNERS / ADIA	DECHRA PHARMACEUTICALS	UNITED KINGDOM	Life Sciences	EQT completed the take-private acquisition of Dechra Pharmaceuticals. The strategic rationale for taking Dechra private was to support its long-term growth away from the volatility of public markets. In early 2023, Dechra faced headwinds from "wholesaler de-stocking" in the US, which hit its share price
06/2023	NOVO NORDISK	BIOCORP	FRANCE	Life Sciences	The acquisition of Biocorp by Novo Nordisk, achieved through the purchase of Bio Jag's 45.3% stake and a subsequent mandatory public tender offer, marks a significant shift in strategy, transitioning from a collaborative research and development model to a proprietary technology platform
04/2023	HALMA	APRIOMED	SWEDEN	Life Sciences	The successful acquisition of AprioMed by IZI Medical Products represents a tactical expansion of Halma’s healthcare portfolio in the interventional radiology segment. This transaction marks the integration of AprioMed’s highly specialized bone biopsy technology, effectively widening the technical operational depth available to IZI Medical’s global clinical customer base
04/2023	SARTORIUS	POLYPLUS	France	Life Sciences	Sartorius Stedim Biotech has reached a definitive agreement to acquire one hundred percent of the share capital of Polyplus from private equity sponsors ArchiMed and Warburg Pincus. This landmark transaction is structured as a full buyout, effectively transferring ownership from financial sponsors to a strategic corporate acquirer

REFERENCES

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of LIBERTY DENTAL GROUP by OAKLEY CAPITAL INVESTMENTS are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Acquirer: oakley capital investments